Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21162496 | 0.87 | ERN1 (0.59) | S1PR5LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL28399722 | 0.86 | LMNA (0.52) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL412514 | 0.84 | MRGPRX4 (0.53) | S1PR5LMNAMRGPRX4NPC1PTGER1 | |
| SCHEMBL30719648 | 0.84 | MRGPRX4 (0.53) | S1PR5LMNAMRGPRX4NPC1PTGER1 | |
| SCHEMBL29721165 | 0.83 | SLC2A1 (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8728948 | 0.83 | SLC2A1 (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL1462187 | 0.83 | S1PR5 (0.56) | S1PR5LMNAMRGPRX4ERN1NPC1 | |
| SCHEMBL29510827 | 0.83 | S1PR5 (0.56) | S1PR5LMNAMRGPRX4ERN1NPC1 | |
| SCHEMBL8993237 | 0.82 | ERN1 (0.58) | S1PR5LMNAMRGPRX4ERN1 | |
| SCHEMBL3212416 | 0.82 | SLC2A1 (0.46) | S1PR5ERN1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125417-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4590686-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025149545-A1 | HETEROARYLPHENYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024064779-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2023109461-A1 | BENZOTHIOPHENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-06-22 | — | — | WO | disclosed |
| CN-116265458-A | Benzothiophene derivative, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-20 | — | — | CN | disclosed |
| US-20230097678-A1 | NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2023-03-30 | — | — | US | disclosed |
| EP-4110776-A1 | NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2023-01-04 | — | — | EP | disclosed |
| CN-115151538-A | Macrocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-10-04 | — | — | CN | disclosed |
| US-20170080095-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2017-03-23 | — | — | US | disclosed |
| EP-0772585-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996004233-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
| EP-0423520-B1 | Liquid crystalline composition for the use in a twisted nematic cell | MERCK PATENT GMBH (DE) | 1995-08-02 | — | — | EP | disclosed |
| US-4803273-A | HERBICIDES | ICI AUSTRALIA LIMITED (AU) | 1989-02-07 | — | — | US | disclosed |
| US-4655819-A | Quinoxalinyloxy phenoxy proprionic acid derivatives as selective herbicides | ICI AUSTRALIA LIMITED (AU) | 1987-04-07 | — | — | US | disclosed |
| US-4649160-A | HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1987-03-10 | — | — | US | disclosed |
| EP-0060607-B1 | 2-(2-HALO-4-(6-HALOQUINOXALIN-2-YLOXY)PHENOXY)PROPIONATES, PROCESS FOR THEIR SYNTHESIS, HERBICIDAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS HERBICIDES | ICI AUSTRALIA LIMITED (AU) | 1985-08-28 | — | — | EP | disclosed |
| EP-0041233-B1 | SUBSTITUTED PHENOXY-AMINOPROPANOL DERIVATIVES, INTERMEDIATES AND PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-15 | — | — | EP | disclosed |
| EP-0060607-A1 | 2-(2-halo-4-(6-haloquinoxalin-2-yloxy)phenoxy)propionates, process for their synthesis, herbicidal compositions containing them and their use as herbicides | ICI AUSTRALIA LIMITED (AU) | 1982-09-22 | — | — | EP | disclosed |
| EP-0041233-A1 | Substituted phenoxy-aminopropanol derivatives, intermediates and processes for their production, and pharmaceutical preparations containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080095-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | ABCB4, LNPK, MBOAT1 | S1PR5 602/4885LMNA 232/4885CYP1A2 4862/4885 |
| US-20230097678-A1 | NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | C1S, C1R, F12 | S1PR5 1401/4885LMNA 1022/4885CYP1A2 47/4885 |
| US-20260125417-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | S1PR5 116/4885LMNA 3593/4885CYP1A2 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.